Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy
European Journal of Neurology · 2024-06 · 31 (6)
DOI: 10.1111/ene.16180 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Neurology, online erschienen am 20.12.2023. Verfasst von Francesco Saccà und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University, Naples, Italy. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and purpose Generalized myasthenia gravis (gMG) continues to present significant challenges for clinical management due to an unpredictable disease course, frequent disease fluctuations, and varying response to therapy. The recent availability of new pharmacologic therapies presents a valuable opportunity to reevaluate how this disease is classified, assessed, and managed and identify new ways to improve the clinical care of patients with gMG.
Methods
Narrative review was made of publications identified via searches of PubMed and selected congresses (January 2000–September 2022).
Results
New consensus definitions are required to ensure consistency, to better characterize patients, and to identify patients who will benefit from specific drugs and earlier use of these agents. There is a need for more frequent, standardized patient assessment to identify the cause of motor function deficits, provide a clearer picture of the disease burden and its impact on daily living and quality of life (QoL), and better support treatment decision‐making. Novel approaches that target different components of the immune system will play a role in more precise treatment of patients with gMG, alongside the development of new algorithms to guide individualized patient management. Conclusions gMG has a physical, mental, and social impact, resulting in a considerable burden of disease and substantially decreased QoL, despite standard treatments. The availability of novel, targeted treatments that influence key pathological mediators of gMG, together with new biomarkers, offers the potential to optimize patient management and ultimately enables a greater number of patients to achieve minimal manifestation status and a reduced burden of disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University, Naples, Italy.
- Reference Center of Neuromuscular Disorders and ALS, Timone University Hospital, Assistance Publique-Hopitaux de Marseille, Marseille, France.
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
- Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau and Biomedical Research Institute Sant Pau, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain.
- Department of Neurology, St. Josef Hospital of Ruhr-University Bochum, Bochum, Germany.
ORCID-Profile: Francesco Saccà, Elena Cortés-Vicente, Christiane Schneider-Gold
Zitieren
APA
Saccà, F., Salort-Campana, E., Jacob, S., Cortés-Vicente, E., & Schneider-Gold, C. (2024). Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy. European Journal of Neurology, 31(6). https://doi.org/10.1111/ene.16180
Vancouver
Saccà F, Salort-Campana E, Jacob S, Cortés-Vicente E, Schneider-Gold C. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy. European Journal of Neurology. 2024;31(6). doi:10.1111/ene.16180
BibTeX
@article{Sacc2024,
author = {Saccà, Francesco and Salort-Campana, Emmanuelle and Jacob, Saiju and Cortés-Vicente, Elena and Schneider-Gold, Christiane},
title = {Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {6},
doi = {10.1111/ene.16180}
}
EUVIMED